Abstract
Over the past two years, the University of Ljubljana and the Republic of Slovenia’s public agency, the Slovenian Research and Innovation Service (ARIS), have acknowledged and cel-ebrated several exceptional accomplishments in viral recep-tor research. These achievements are considered among the finest by both the University of Ljubljana and ARIS. The sig-nificance of these achievements lies in the research findings, which indicate that the EBV-BILF1 receptor encoded by the Epstein-Barr virus (EBV) could become a promising new drug target for EBV. Additionally, the research suggests pigs repre-sent a great model for further investigations (1–4). Humani herpesvirus Epstein-Barr (EBV) in njegovi prašičji homologi razkrivajo ohranjeni mehanizem receptorske endocitoze: nov vpogled v virusno izmikanje imunskemu sistemu in potencialne protivirusne terapije? Univerza v Ljubljani in Javna agencija za znanstvenorazi-skovalno in inovacijsko dejavnost Republike Slovenije (ARIS) sta v preteklih dveh letih prepoznali in počastili več izjemnih dosežkov na področju raziskovanja virusnih receptorjev. Ti dosežki – tako na Univerzi v Ljubljani kot na ARIS-u – sodi-jo med najboljše. Njihov pomen izhaja iz raziskav, ki kažejo na to, da bi se lahko receptor EBV-BILF1, kodiran na virusu Epstein-Barr (EBV), uporabljal kot obetavna nova tarča za zdravljenje EBV. Poleg tega raziskava predlaga uporabo pra-šičev kot modela za nadaljnje preiskave (1–4).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
